Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8600438 | 0.86 | TRIM24 (0.53) | PKMGAAALDH1A1MEN1KMT2A | |
| SCHEMBL1591102 | 0.84 | GAA (0.64) | PKMGAAALDH1A1MEN1KMT2A | |
| SCHEMBL14333569 | 0.84 | GAA (0.60) | PKMGAAALDH1A1MEN1KMT2A | |
| SCHEMBL10154069 | 0.81 | PKM (0.66) | PKMGAAALDH1A1MEN1KMT2A | |
| SCHEMBL1925311 | 0.76 | PKM (0.59) | PKMGAAALDH1A1MEN1KMT2A | |
| SCHEMBL434054 | 0.74 | TRIM24 (0.54) | PKMGAAALDH1A1MEN1KMT2A | |
| SCHEMBL30222138 | 0.74 | TRIM24 (0.54) | PKMGAAALDH1A1MEN1KMT2A | |
| SCHEMBL6532369 | 0.74 | GAA (0.50) | PKMGAAALDH1A1LMNAPOLB | |
| SCHEMBL578369 | 0.73 | LMNA (0.60) | PKMGAAALDH1A1MEN1KMT2A | |
| SCHEMBL8999096 | 0.73 | TRIM24 (0.49) | PKMGAAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645533-B1 | TDO2 AND IDO1 INHIBITORS | GENENTECH INC (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023202583-A1 | FXR REGULATOR AND USE THEREOF | 北京大学 | 2023-10-26 | — | — | WO | disclosed |
| CN-116903559-A | FXR modulators and uses thereof | 北京大学 | 2023-10-20 | — | — | CN | disclosed |
| US-11603373-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| CN-114181199-A | 2, 4-disubstituted pyrimidine derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2021260722-A1 | DESIGN, SYNTHESIS OF NOVEL OXYINDOLE INHIBITORS OF DENV RNA DEPENDENT RNA POLYMERASE | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2021-12-30 | — | — | WO | disclosed |
| EP-3645533-A1 | TDO2 AND IDO1 INHIBITORS | Genentech, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200123163-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2019005559-A1 | TDO2 AND IDO1 INHIBITORS | GENENTECH, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-9931327-B2 | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| CN-100345829-C | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| CN-1681795-A | Pyrimidyl sulfonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | CN | disclosed |
| EP-1527051-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011443-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
| EP-0623614-B1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1998-02-25 | — | — | EP | disclosed |
| US-5512594-A | ADMINISTERING TO TREAT A MEDICAL CONDITION MEDIATED BY ONE OR MORE LEUKOTRIENES | ZENECA LIMITED (GB) | 1996-04-30 | — | — | US | disclosed |
| US-5478842-A | Antiinflammatory agents, antiallergens, drugs for treatment of diseases mediated by leukotrienes | ZENECA LIMITED (GB) | 1995-12-26 | — | — | US | disclosed |
| WO-1994025453-A1 | 4-ARYL-4-HYDROXY-TETRAHYDROPYRANS AND 3-ARYL-3-HYDROXY-TETRAHYDROFURANS AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603373-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | PKM 4209/4885GAA 2380/4885ALDH1A1 855/4885 |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ACKR3, GPR17, CCL11 | PKM 1904/4885GAA 2860/4885ALDH1A1 2245/4885 |
| US-20200123163-A1 | TDO2 and IDO1 Inhibitors | IDO1, TDO2, IDO2 | PKM 4209/4885GAA 2380/4885ALDH1A1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.